Dimensione Ricerca s.r.l. Report issue

For profit Phase 3
Founded: Rome Italy (1990)
Status: Left NME R&D (2000)

Organization Overview

First Clinical Trial
1999
NCT00473213
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1999

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

peginterferon beta-1a (Plegridy) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1